

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kendall M. MOHLER; Dauphine S. BARONE,
Jacques J. PESCHON, Mary K. KENNEDY and
John D. PLUENNEKE

Serial No.: --to be assigned--
(Divisional of 09/921,667)

Group Art Unit No.: --to be assigned--

Filed: August 26, 2003

Examiner: --to be assigned--

For: METHODS FOR TREATING AUTOIMMUNE AND
CHRONIC INFLAMMATORY CONDITIONS USING
ANTAGONISTS OF CD30 OR CD30L

Docket No.: 2959-B

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References Cited by Applicants" on a modified PTO-1449 form.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/921,667, filed August 3, 2001. The present application is a divisional of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).]

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,



Patricia Anne Perkins
Agent for Applicants
Registration No.: 34,693
Phone: (206) 265-4782
Date: August 26, 2003

Please send all future correspondence to:

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
(206) 587-0430

Form PTO-1449U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2959-B

SERIAL NO.

--to be assigned--

Div of 09/921,667

INFORMATION DISCLOSURE CITATION

APPLICANT

Kendall M. MOHLER et al.

FILING DATE

August 26, 2003

GROUP

--to be assigned--

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,304,635	04/19/94	Imam et al.			
	A2	5,480,981	01/02/96	Goodwin et al.			
	A3	5,677,430	10/14/97	Goodwin et al.			
	A4	5,840,869	11/24/98	Mosley et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	B1	WO 03/043583A2	5/30/03	WIPO				
	B2	EP 0460846A	12/11/91	EPO				X
	B3	WO 99/40187	08/12/99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Bengtsson Å. et al., "Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation," <i>J. Leukoc. Biol.</i> 58:683-689 (1995).						
	C2	Blom AB et al., "Immune complexes, but not streptococcal cell walls or zymosan, cause chronic arthritis in mouse strains susceptible for collagen type II auto-immune arthritis," <i>Cytokine</i> 1999; 11:1046-1056, XP-001089856.						
	C3	Caligaris-Cappio F. et al., "Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity," <i>Clin. Exp. Rheumatol.</i> 13:339-343 (1995).						
	C4	Durkop H. et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease," <i>Cell</i> 68:421-427 (1992).						
	C5	Erickson S. L. et al., "Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice," <i>Nature</i> 372:560-563 (1994).						
	C6	Gilfillan M. C. et al., "Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines," <i>J. Immunol.</i> 160:2180-2187 (1998).						
	C7	Gruss H-J et al., "Biological roles of CD30 ligand in CD30+ malignant lymphomas and T cell-dependent immune responses," <i>Exp Hematol (Charlottesville)</i> , 1995, 23:851, XP008005895.						
	C8	Hamann D. et al., "CD30 expression does not discriminate between human Th1- and Th2-type T cells," <i>J. Immunol.</i> 156:1387-1391 (1996).						
	C9	Horie R. and Watanabe T., "CD30: expression and function in health and disease," <i>Semin. Immunol.</i> 10:457-470 (1998).						
	C10	Joe B. and Wilder R. L., "Animal models of rheumatoid arthritis," <i>Mol. Med. Today</i> 5:367-369 (1999).						

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Supplemental Sheet)</i>		ATTY. DOCKET NO. <p style="text-align: center;">2959-B</p>	SERIAL NO. <p style="text-align: center;">-- to be assigned-- (Div of 09/921,667)</p>
		APPLICANT <p style="text-align: center;">Kendall M. MOHLER et al.</p>	
		FILING DATE <p style="text-align: center;">August 26, 2003</p>	GROUP <p style="text-align: center;">To be assigned</p>
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
C11	Koon H. B. and Junghans R. P., "Anti-CD30 antibody-based therapy," <i>Curr. Opin. Oncol.</i> 12:588-593 (2000).		
C12	Körner H. et al., "Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system," <i>Eur. J. Immunol.</i> 27:1973-1981 (1997).		
C13	Körner H. et al., "Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting," <i>J. Exp. Med.</i> 186(9):1585-1590 (1997).		
C14	Kurts C. et al., "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells," <i>Nature</i> 398:341-344 (1999).		
C15	Liu A. Y. et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> 84:3439-3443 (1987).		
C16	Marino M. W. et al., "Characterization of tumor necrosis factor-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> 94:8093-8098 (1997).		
C17	Mendel I. et al., "A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2 ^b mice: fine specificity and T cell receptor V β expression of encephalitogenic T cells," <i>Eur. J. Immunol.</i> 25:1951-1959 (1995).		
C18	Mori L. et al., "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice," <i>J. Immunol.</i> 157:3178-3182 (1996).		
C19	Nakamura T. et al., "Reciprocal regulation of CD30 expression on CD4 ⁺ T cells by IL-4 and IFN- γ ," <i>J. Immunol.</i> 158:2090-2098 (1997).		
C20	Peschon J. J. et al., "TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation," <i>J. Immunol.</i> 160:943-952 (1998).		
C21	Pfeffer K. et al., "Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to <i>L. monocytogenes</i> infection," <i>Cell</i> 73:457-467 (1993).		
C22	Riechmann L. et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (1988).		
C23	Romagnani S. et al., "CD30 and type 2 T helper (Th2) responses," <i>J. Leukoc. Biol.</i> 57:726-730 (1995).		
C24	Romagnani S., "Biology of human T _H 1 and T _H 2 cells," <i>J. Clin. Immunol.</i> 15(3):121-129 (1995).		
C25	Rothe J. et al., "Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by <i>Listeria monocytogenes</i> ," <i>Nature</i> 364:798-802 (1993).		
C26	Smith C. A. et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> 73:1349-1360 (1993).		
C27	Sundarapandiyan K. et al., "Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells," <i>J. Immunol. Methods</i> 248:113-123 (2001).		
C28	Wiley S. R. et al., "Reverse signaling via CD30 ligand," <i>J. Immunol.</i> 157:3635-3639 (1996).		
C29	Winter G. and Harris W. J., "Antibody-based therapy," <i>TiPS</i> 14:139-143 (1993).		
C30	Yamamoto J. et al., "CD30 expression on circulating memory CD4 ⁺ T cells as a Th2-dominated situation in patients with atopic dermatitis," <i>Allergy</i> 55:1011-1018 (2000).		
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			